InflaRx N.V. Stock News

InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev

InflaRx (IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today interim results from the first 30 patients trea

InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin

Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1.

Inflarx (NASDAQ:IFRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, anal

LMP Automotive Holdings (NASDAQ:LMPX) +35%.AgEagle Aerial Systems (NYSEMKT:UAVS) +27%.Soligenix (NASDAQ:SNGX) +25% on positive SGX301 data.Secoo Holding (NASDAQ:SECO) +26% on share repurchase progra

Thursday's top analyst upgrades and downgrades included Carvana, Caterpillar, Dollar General, DraftKings, eBay, Facebook, Microsoft, Schlumberger, Spotify and Tesla.

Citing "imminent data" from its COVID-19 trial and an autoimmune disorder study, Raymond James' Steven Seedhouse has upgraded InflaRx (NASDAQ:IFRX) to Outperform with a $10 (85% upside) price

End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of.

End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma...

Inflarx NV (NASDAQ:IFRX)’s stock price traded up 10.2% during mid-day trading on Friday . The company traded as high as $5.85 and last traded at $5.84, 1,112,450 shares were traded during trading. A

Inflarx NV (NASDAQ:IFRX) has been assigned an average rating of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts hav